Ratan Capital Management LP Grows Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Ratan Capital Management LP boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 28.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,050 shares of the medical research company’s stock after purchasing an additional 1,550 shares during the period. Thermo Fisher Scientific makes up approximately 0.6% of Ratan Capital Management LP’s investment portfolio, making the stock its 28th biggest holding. Ratan Capital Management LP’s holdings in Thermo Fisher Scientific were worth $3,618,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Capital Investment Advisors LLC boosted its position in Thermo Fisher Scientific by 15.4% in the 4th quarter. Capital Investment Advisors LLC now owns 1,335 shares of the medical research company’s stock valued at $695,000 after buying an additional 178 shares during the period. BCS Wealth Management bought a new position in Thermo Fisher Scientific in the fourth quarter worth approximately $218,000. Signal Advisors Wealth LLC raised its position in Thermo Fisher Scientific by 18.3% during the 4th quarter. Signal Advisors Wealth LLC now owns 1,210 shares of the medical research company’s stock valued at $630,000 after purchasing an additional 187 shares in the last quarter. Breakwater Capital Group grew its position in shares of Thermo Fisher Scientific by 8.8% during the 4th quarter. Breakwater Capital Group now owns 653 shares of the medical research company’s stock worth $340,000 after buying an additional 53 shares in the last quarter. Finally, SeaCrest Wealth Management LLC increased its stake in shares of Thermo Fisher Scientific by 26.7% during the fourth quarter. SeaCrest Wealth Management LLC now owns 1,743 shares of the medical research company’s stock valued at $907,000 after buying an additional 367 shares during the period. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $407.38 on Thursday. The firm has a market cap of $153.78 billion, a price-to-earnings ratio of 24.64, a PEG ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a one year low of $401.75 and a one year high of $627.88. The firm’s fifty day moving average is $458.36 and its two-hundred day moving average is $512.38. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.10 by $0.05. The business had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company’s revenue for the quarter was up .2% on a year-over-year basis. During the same period in the prior year, the company posted $5.11 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were paid a $0.43 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.42%. The ex-dividend date of this dividend was Friday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.09%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on TMO. Raymond James restated an “outperform” rating and issued a $667.00 price target (up previously from $650.00) on shares of Thermo Fisher Scientific in a report on Monday, February 3rd. Wells Fargo & Company lowered their target price on Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating for the company in a report on Thursday, April 24th. UBS Group reduced their price target on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating for the company in a research report on Thursday, April 24th. Morgan Stanley lifted their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a research note on Friday, January 31st. Finally, Argus lowered their price target on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating on the stock in a report on Tuesday, April 29th. Five equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $607.43.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president now owns 23,167 shares in the company, valued at $9,960,188.31. The trade was a 1.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Michael A. Boxer sold 3,775 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the sale, the senior vice president now directly owns 10,816 shares of the company’s stock, valued at $5,759,736.32. This represents a 25.87% decrease in their position. The disclosure for this sale can be found here. Insiders sold 14,075 shares of company stock valued at $7,305,942 over the last 90 days. 0.33% of the stock is currently owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.